Rebecka Hellsten
Malmoe, M, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Editor's Note: Therapeutic Targeting of Nuclear γ-Tubulin in RB1-Negative Tumors.
Journal: Molecular cancer research : MCR
Published: August 23, 2024
The STAT3 inhibitor GPB730 enhances the sensitivity to enzalutamide in prostate cancer cells.
Journal: Translational oncology
Published: May 04, 2022
Nuclear expression of pSTAT3Tyr705 and pSTAT3Ser727 in the stromal compartment of localized hormone-naïve prostate cancer.
Journal: Pathology, research and practice
Published: December 07, 2021
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: October 07, 2020
STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population.
Journal: Scientific reports
Published: March 07, 2020
The STAT3 inhibitor galiellalactone inhibits the generation of MDSC-like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors.
Journal: The Prostate
Published: February 08, 2019
Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
Journal: PloS one
Published: May 17, 2016
Expression of STAT3 in Prostate Cancer Metastases.
Journal: European urology
Published: April 26, 2016
Preclinical Characterization of 3β-(N-Acetyl l-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer.
Journal: Journal of medicinal chemistry
Published: April 26, 2016
The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
Journal: European urology
Published: April 16, 2015
Last Updated: 09/26/2026